CASP3 and in situ carcinoma: There was a clear dose-dependent caspase activation, as detected with the increased enzymatic activity of caspases-3 and caspase-7 in RCC cells treated for 12 h by DZ-CIS in the range of 8 μM to 16 μM (Fig. 2A).